Results 141 to 150 of about 63,224 (282)

Regulatory Function of Proto-oncogene MDM2 on the Liver Growth and Morphogenesis in Zebrafish (Danio rerio)

, 2007
在許多癌症中均發現MDM2(mouse double minute 2)基因有過量表現之情形，這是因為MDM2基因可以抑制腫瘤抑制基因p53的表現量。除此以外，目前的研究也發現MDM2可以參與其他獨立於p53的功能，其在細胞週期調控、分化、細胞命運的決定、DNA的修補、基本轉錄調控及其他方面的功能上均扮演重要角色。此外，在不同的模式動物如轉殖鼠、果蠅跟斑馬魚之研究顯示過量表現MDM2會抑制生長及影響細胞分化。因此本實驗中我們利用肝臟發綠螢光的轉基因斑馬魚 ...
Huang, Shin-Jie, 黃信傑
core  

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress

British Journal of Haematology, EarlyView.
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo, Maria Georgiou, Donal P. McLornan, Claire N. Harrison   +3 more
wiley   +1 more source

Mdm2 p53 binding protein homolog (MDM2) [PDF]

Science-Business eXchange, 2010
openaire   +1 more source

PTEN homozygous deletion is a negative prognostic factor in tumor treating fields‐treated glioblastoma, IDH wildtype patients

Brain Pathology, EarlyView.
In a molecularly confirmed cohort of 64 newly diagnosed, TTFields‐treated glioblastomas, IDH‐wildtype, homozygous PTEN deletion was associated with markedly shorter overall survival (368 vs. 603 days) and remained an independent adverse prognostic factor.
Jakob Nückles, Claudius Jelgersma, Christin Siewert, Brendan Osberg, Simone Schmid, Arend Koch, Eilís Perez, Daniel Teichmann, Martin Misch, Anna‐Gila Karbe, Susanne Ukrow, Patrick N. Harter, Ruth M. Stassart, Peter Vajkoczy, Julia Onken, David Capper   +15 more
wiley   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

miR-1305 Inhibits The Progression Of Non-Small Cell Lung Cancer By Regulating MDM2

Cancer Management and Research, 2019
Yuxing Cai,1 Yi Hao,2 HaiFeng Ren,3 ZhiGuo Dang,3 Hui Xu,1 Xiangfei Xue,1 Yan Gao3 1Department of Respiratory Medicine, Baoji Central Hospital, Baoji, 721008, People’s Republic of China; 2Department of Pediatric Surgery, Baoji Maternal and Child ...
Cai Y, Hao Y, Ren H, Dang Z, Xu H, Xue X, Gao Y   +6 more
doaj  

Extracellular vesicles in pharmacology: Innovations in drug delivery and therapeutic applications in cancer

British Journal of Pharmacology, EarlyView.
Extracellular vesicles (EVs) are a diverse population of membrane nanoparticles secreted by nearly all cell types, playing a key role in intercellular communication by transferring bioactive macromolecular cargo. In cancer, EVs shape both the local tumour microenvironment and distant premetastatic niches.
Evangelia Pantazaka, Georgios Sivvas, Evangelia Papadimitriou, Constantinos M. Mikelis   +3 more
wiley   +1 more source

MDM2 Oncogene Copy Number Alterations in Chronic Lymphocytic Leukemia

Turkish Journal of Hematology, 2019
Pathum Sookaromdee, Viroj Wiwanitkit
doaj   +1 more source

Association of MDM2 rs2279744 and rs937282 polymorphisms with breast cancer susceptibility and circulating MDM2 and p53 levels in Bangladeshi women: A case-control study. [PDF]

PLoS One
Chowdhury MH, Islam F, Khan AA, Siddique MA, Hasan NB, Samrat MI, Tanisha MH, Tasnim J, Mahjabin S, Islam MN, Haque MA.   +10 more
europepmc   +1 more source

Long non‐coding RNAs at the crossroads of inflammation, cancer and angiogenesis: Molecular mechanisms and their potential as therapeutic targets

British Journal of Pharmacology, EarlyView.
Long non‐coding RNAs (lncRNAs), a broad class of non‐protein‐coding RNAs, are characterized as new regulators of gene expression at the epigenetic, transcriptional, and post‐transcriptional level. Thus, lncRNAs are involved in the regulation of physiological processes and the development of human diseases and cancer by modulating proinflammatory ...
Charlie Leboff, Pamela Calle‐Mendoza, Maria Hatziapostolou, Christos Polytarchou   +3 more
wiley   +1 more source